(Date:12/5/2008)...fer heart problems, study says , , FRIDA...ly lung disease idiopathic pulmonary fibrosis (IPF...the disease to suffer severe cardiac events such a..., "If you look at them over time, people with IP... coronary syndrome, which is a greater increase th...
(Date:12/5/2008)...For many, city living is at its,finest during the...rther,glamorized by the festive parties, larger t...the joyful atmosphere. However, for many single ci...an emotionally trying time,filled with expectatio...,romance during the holidays have developed a neg...
(Date:12/5/2008)...- Norgine, the leading European specialty pharmace...anted Medical Futures the exclusive rights to mark... patent-protected product developed by Norgine for...tuations where a clean bowel is required. The prod...A by its partner Salix Pharmaceuticals. , In re...
(Date:12/5/2008).../ - QLT Inc. (NASDAQ: QLTI ; TSX: QLT) announced... bid circular (the "Circular") to its shareholders...n" tender offer for up to US$50 million of common ...The Circular is being filed with the securities re...da. Under the terms of the tender offer, sharehold...
Breaking Medicine News(10 mins):Health News:Lung Disease Tied to Increased Risk for Cardiac Events 2Health News:Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures 2Health News:Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures 3Health News:Medical Futures partners with Norgine for MOVIPREP(R) in Canada 2Health News:QLT announces commencement of tender offer 2Health News:QLT announces commencement of tender offer 3Health News:QLT announces commencement of tender offer 4Health News:QLT announces commencement of tender offer 5(Date:12/3/2008).... Jude treatment alleviates long-term anemia and o...plications , , MEMPHIS, Tenn., Dec. 3 /PRN...nsert a corrective gene into mouse blood cells, sc...have alleviated sickle cell disease pathology. In ...ted mice showed essentially no difference from nor...
(Date:12/3/2008)..., Del., Dec. 3 Isogen, a contract ...erile filling, announced it has retained a,strate... to meet the global,biopharma demand for Isogen,s...d a successful first round series of capital,inve...acility in Q1 2009 to,deliver on the previously u...
(Date:12/3/2008)...EGO, Dec. 3 Vical Incorp...sive, binding letter of intent with EIP,Eczacibas...g of the company,s,Allovectin-7(R) immunotherapeu...epublic of Northern Cyprus. EIP has agreed to obta...ritory and to pay Vical upfront and milestone paym...
(Date:12/2/2008)...DGE, Mass., Dec. 2 Biopu...that the U.S. Naval Medical Research Center,(NMRC...n (FDA) a revised,investigational new drug (IND) ...mpany,s oxygen therapeutic Hemopure(R) [hemoglobin...ttlefield treatment of trauma patients. The study ...
Breaking Medicine Technology:Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 2Gene Therapy Corrects Sickle Cell Disease in Laboratory Study 3Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 2Isogen Retains Strategic Partner Sheridan Road Financial to Meet Global Biopharma Demand 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 2Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 3Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 4Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey 5U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3Sage Software Healthcare Inc Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 7649 1Sage Software Healthcare Inc Announces Intergy by Sage and Intergy EHR by Sage installations for 2007 7649 2Infant Development Program from EASY Baby Takes On the Sixty Percent Increase in Developmental Delays in Children 7647 1Infant Development Program from EASY Baby Takes On the Sixty Percent Increase in Developmental Delays in Children 7647 2Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 1Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 2Advances in Blood Cancer Therapy to be Highlighted at American Society of Hematology Conference 7645 3Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 1Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 2Teen Birth Rates Up for First Time in 14 Years U S Reports 7643 3...PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - Gero...esentation of,research studies indicating that GRN...C)-based therapeutic for the treatment of,spinal c...mune,system., Presented by Geron scientist Ross Ok...ieties meeting in San Diego, the findings,could me...
...he Netherlands, June 11, 2007-Sugammadex - the nov...eveloped by Organon,the human healthcare business...pivotal trial a 9-12 times faster reversal of,neur...hout evidence,of post operative residual curarizat..., 2 The results of this pivotal Aurora trial,were ...
Other Medicine Technology:Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 2Organon's Sugammadex Demonstrated a 9-12 Times Faster Recovery in,Phase III Pivotal Trial Compared to Neostigmine 3...ne-125 implant is a combination of innovative desi...e visibility that makes BrachySource I-125 implant...You can be confident that every BrachySource I-125...rvices which is required by clinicians who must me...
...ne-125 implant is a combination of innovative desi...e visibility that makes BrachySource I-125 implant...You can be confident that every BrachySource I-125...rvices which is required by clinicians who must me...
The Double-J Closed Tip Ureteral Stent design revolutionized stenting over 15 years ago. Today, it remains one of the most widely used stents in the world. An exclusive ACMI design allows one-step in
...ternal drainage from the ureteropelvic junction to...e segment with no sideports prevents postoperative...ingrowth of the ureteral wall to the stent. Suppli...-time use. CAUTION: Periodic evaluation is advised...
Medicine Products: